AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02684006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
Study NCT01046916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
Study NCT01262313 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Counseling
Description: Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes.
Study NCT01262313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes.
Study NCT04438928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elevit Pregnancy 2nd & 3rd Trimester
Description: Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
Study NCT04438928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-Supplement
Description: Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
Study NCT01720095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Study NCT02354638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco users
Description: Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
Study NCT02354638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks
Study NCT03444142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide LAR
Description: 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
Study NCT03444142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: .75 mg once weekly subcutaneously before breakfast during 4 weeks.
Study NCT03887091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postwire
Description: Postwire© is a web-based, video platform
Study NCT03957538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality angiogram experience video
Description: The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
Study NCT02665728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Study NCT00567788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost-Bimatoprost
Description: latanoprost 0.005% once daily followed by bimatoprost 0.03%
Study NCT00567788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoporost-Latanoprost
Description: bimatoprost 0.03% once daily followed by latanoprost 0.005%
Study NCT03768739 — intervention group
Intervention type: PROCEDURE
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
Study NCT03296163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02 (Bevacizumab Biosimilar Drug)
Description: 15 mg/kg IV every 3 weeks on Day 1
Study NCT03296163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Avastin®
Description: 15 mg/kg IV every 3 weeks on Day 1
Study NCT03296163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
Study NCT03296163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
Study NCT03296163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
Study NCT03296163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
Study NCT04055194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid tablets
Description: Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
Study NCT04055194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
Study NCT04295889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Approach A (PeeSpot urine collection device).
Description: The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
Study NCT04295889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Approach B (ACR | EU Test kit).
Description: The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app.
Study NCT04600960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
Study NCT03844451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
Study NCT03844451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Epinephrine
Description: At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
Study NCT03844451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine and Epinephrine
Description: At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
Study NCT01584947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine lozenge taken 3 times a day for two weeks
Study NCT01584947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge taken three times a day for two weeks
Study NCT05684679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometer plus Chest physiotherapy
Description: Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
Study NCT05684679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise plus Chest physiotherapy
Description: Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
Study NCT03380468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin plus pemetrexed
Description: cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
Study NCT03178656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: continuous application of the drugs
Study NCT03178656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: curative resection
Study NCT02676544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere microspheres
Description: This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
Study NCT04040101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone-based balance training system
Description: use smartphone application to training balance
Study NCT04040101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: smartphone-based balance training system
Description: use smartphone application to training balance
Study NCT02442817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
Study NCT04582422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch Therapy
Description: During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
Study NCT01422434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90105 = calcipotriol + betamethasone dipropionate
Description: Applied once daily for 4 weeks.
Study NCT01422434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovonex® = calcipotriol
Description: Applied twice daily for 4 weeks.
Study NCT01422434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rinderon® - DP = betamethasone dipropionate
Description: Applied once daily for 4 weeks.
Study NCT02734017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacist-led standardized medication review
Description: the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
Study NCT00703261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
Study NCT00703261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
Study NCT03099655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attain Stability Quad Left Ventricular Pacing Lead
Description: cardiac stimulation
Study NCT01988337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
Study NCT01988337 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mock treatment
Description: For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material.
Study NCT03191435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training.
Description: Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
Study NCT03191435 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inspiratory muscle
Description: Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
Study NCT02886494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAC treatment
Description: BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
Study NCT02886494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched vehicle
Description: BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
Study NCT00576849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced HES 130/0.42
Description: Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Study NCT00576849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced HES 130/0.42
Description: Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Study NCT00576849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% HES 130/0.4 prepared in saline solution
Description: Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Study NCT02306018 — intervention group
Intervention type: DEVICE
Intervention: EV1000™/volumeView™
Study NCT01803464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude vibration
Description: Children will receive a daily low-magnitude vibration treatment.
Study NCT01803464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Children who are candidates to receive Botox as part of their standard of care.
Study NCT00580931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: 1500 mg twice a day for 6 months
Study NCT00580931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enduramide placebo
Description: 1 tab twice a day
Study NCT01262274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: ANA is given 1mg daily for 24 weeks.
Study NCT01262274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole plus tegafur-uracil
Description: ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
Study NCT01802762 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeMo Patch and NeMo Probe
Description: A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
Study NCT03162861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane inhalation for anesthesia
Description: The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
Study NCT03162861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol for anesthesia
Description: The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
Study NCT03808896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stylet-assisted epiglottic lifting
Description: use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
Study NCT03808896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bougie-assisted intubation
Description: use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
Study NCT03142477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapeutic touch
Description: Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
Study NCT03142477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Description: Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01548573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplant
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT01548573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV or PO
Study NCT00673452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: 60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
Study NCT00673452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
Study NCT00813124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
Study NCT00813124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
Study NCT00813124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
Study NCT00813124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.